Zhang Xi-tong, Zhang Hong-yi, Zhang Wei, Hong Duo, An Jian-li, Xia Yong-hui, Xu Ke
Department of Interventional Radiology, the First Hospital of China Medical Univercity, Shenyang 110001, China.
Zhonghua Yi Xue Za Zhi. 2011 Feb 22;91(7):473-6.
To compare the short-term and medium-term result of stent implantation with pharmaceutical thrombolysis in patients with acute superior mesenteric artery occlusion.
From January, 2004 to December, 2008, thirty-five patients diagnosed acute superior mesenteric ischemia, 12 patients treated with stent implantation (interventional therapy group) and 23 patients with pharmaceutical thrombolysis (thrombolytic therapy group). Interventional therapy group treated with balloon dilatation and stent implantation assisted with anticoagulation, antiplatelet and vascular dilation agents. Thrombolytic therapy group used urokinase combined with anticoagulation, antiplatelet and vascular dilation agents. All patients had taken clopidogrel and aspirin orally after discharged and followed up. The clinical effects of both groups were evaluated separately and the Fisher exact test was used to analysis the significant differences.
In the 23 cases of thrombolytic therapy group, 7 cases was effective, 16 cases was ineffective (7 cases aggravated or died, 9 cases turn to surgical operation). In the 12 cases of interventional therapy group, 10 cases treated with stent implantation (1 case died of acute cardiac infarction 3 days after interventional operation), 2 cases failed in recanalizing. All patients were followed up after discharged (range 1 - 48 months, mean 15 ± 12 months), 1 case in thrombolytic therapy group was stable, 6 cases died of the recurrence of acute superior mesenteric artery occlusion; 7 cases in interventional therapy group was stable, 1 case died of acute cardiac infarction 20 months after interventional operation (intestinal ischemia not appeared), 1 case had intestinal ischemia reoccurred and recovered by superior mesenteric artery thrombolysis.
In the treatment of acute superior mesenteric ischemia, stent implantation was obviously superior to pharmaceutical thrombolysis in improving intestinal ischemia and survival, therefore it could provided a reliable choice for the patients who had not appeared intestinal necrosis.
比较急性肠系膜上动脉闭塞患者支架植入术与药物溶栓的短期和中期结果。
2004年1月至2008年12月,35例诊断为急性肠系膜上动脉缺血的患者,12例接受支架植入术(介入治疗组),23例接受药物溶栓(溶栓治疗组)。介入治疗组采用球囊扩张和支架植入术,并辅以抗凝、抗血小板和血管扩张剂。溶栓治疗组使用尿激酶联合抗凝、抗血小板和血管扩张剂。所有患者出院后均口服氯吡格雷和阿司匹林并进行随访。分别评估两组的临床疗效,并采用Fisher精确检验分析差异显著性。
溶栓治疗组23例中,有效7例,无效16例(7例病情加重或死亡,9例转为手术治疗)。介入治疗组12例中,10例行支架植入术(1例介入术后3天死于急性心肌梗死),2例再通失败。所有患者出院后均进行随访(随访时间1 - 48个月,平均15±12个月),溶栓治疗组1例病情稳定,6例死于急性肠系膜上动脉闭塞复发;介入治疗组7例病情稳定,1例介入术后20个月死于急性心肌梗死(未出现肠缺血),1例肠缺血复发,经肠系膜上动脉溶栓后恢复。
在急性肠系膜上动脉缺血的治疗中,支架植入术在改善肠缺血和提高生存率方面明显优于药物溶栓,因此可为未出现肠坏死的患者提供可靠选择。